|Anti-Human CTLA4 Recombinant Antibody (Yervoy)
- Product Overview
- Recombinant monoclonal antibody to CTLA4. Ipilimumab (known as MDX-010 and MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody, and works by activating the immune system by targeting CTLA-4.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy cancer cells.
- The details of the immunogen for this antibody are not available.
- Suitable for use in ELISA, IP, FC, FuncS, Neut, IF and most other immunological methods.
- Specific Activity
- Tested positive against native human antigen.
- Protein Construction
- Immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human γ1-chain), disulfide with human kappa-chain, dimer
- >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
- 4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.
- Antigen Description
- Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
- protein binding;
- CTLA4; cytotoxic T-lymphocyte-associated protein 4; celiac disease 3 , CELIAC3; cytotoxic T-lymphocyte protein 4; CD; CD28; CD152; GSE; ICOS; CD152 isoform; celiac disease 3; cytotoxic T-lymphocyte antigen 4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; GRD4; CTLA-4; IDDM12; CELIAC3;
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.